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Abstract
Background: In patients with septic shock, the presence of an elevated heart rate (HR) after fluid resuscitation
marks a subgroup of patients with a particularly poor prognosis. Several studies have shown that HR control in this
population is safe and can potentially improve outcomes. However, all were conducted in a single-center setting.
The aim of this multicenter study is to demonstrate that administration of the highly beta1-selective and ultrashort-
acting beta blocker landiolol in patients with septic shock and persistent tachycardia (HR ≥ 95 beats per minute
[bpm]) is effective in reducing and maintaining HR without increasing vasopressor requirements.
Methods: A phase IV, multicenter, prospective, randomized, open-label, controlled study is being conducted. The
study will enroll a total of 200 patients with septic shock as defined by The Third International Consensus Definitions
for Sepsis and Septic Shock criteria and tachycardia (HR ≥ 95 bpm) despite a hemodynamic optimization period of
24–36 h. Patients are randomized (1:1) to receive either standard treatment (according to the Surviving Sepsis
Campaign Guidelines 2016) and continuous landiolol infusion to reach a target HR of 80–94 bpm or standard
treatment alone. The primary endpoint is HR response (HR 80–94 bpm), the maintenance thereof, and the
absence of increased vasopressor requirements during the first 24 h after initiating treatment.
Discussion: Despite recent studies, the role of beta blockers in the treatment of patients with septic shock remains
unclear. This study will investigate whether HR control using landiolol is safe, feasible, and effective, and further
enhance the understanding of beta blockade in patients with septic shock.
Trial registration: EU Clinical Trials Register; EudraCT, 2017-002138-22. Registered on 8 August 2017.
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Background
In the early phase of septic shock, overwhelming inflam-
mation leads to vasodilation and capillary leakage, which
decreases cardiac output due to both absolute and relative
hypovolemia [1–3]. These alterations trigger massive sym-
pathetic activation in the attempt to maintain vital organ
perfusion. Tachycardia and vasoconstriction are the hall-
marks of this activation and compensate for systemic
vasodilatation [4]. In the very early phase of the septic in-
sult, tachycardia is the main compensatory mechanism to
maintain cardiac output despite the reduction of preload.
Accordingly, current sepsis guidelines recommend intra-
vascular fluid administration as the first step to counteract
hypotension [4]. Compensatory tachycardia implies pre-
served baroreceptor and chemoreceptor activity, thus the
majority of patients with sepsis rapidly respond to volume
administration with a reduction of tachycardia.
However, some patients with sepsis continue to have
an elevated heart rate (HR) despite adequate fluid
resuscitation. This elevated HR reflects sympathetic
overstimulation resulting from dysregulation of the auto-
nomic nervous system [5–12] in addition to the effect of
exogenous catecholamines [7].
Elevated HR has been associated with a poor outcome,
but it is unclear whether it is a surrogate of disease se-
verity or whether it plays a pathophysiological role that
could be treated to improve patient outcomes [13–16].
Beta-blockers are potential candidates to control HR
and numerous animal models provide a rationale for their
use during sepsis [17–24]. Despite concerns of
hemodynamic decompensation, recent clinical studies
using esmolol in patients with sepsis [10, 25–34] suggest
that control of HR can be safely achieved with
beta1-selective beta-blockers. These studies reported a de-
crease in HR with limited reduction of cardiac output, im-
proved stroke volume and lactate levels, and stabilization
or improvement of organ dysfunction [10, 28–30, 32].
Furthermore, the combined use of beta-blockers and
vasopressors appears to be safe and does not appear to in-
crease the need for vasopressor support or impair micro-
circulation [26, 27, 34]. However, all of the previously
reported studies were conducted in single centers with
relatively small sample sizes and only one study included a
Caucasian population.
Landiolol, the beta-blocker used in our study, is a
highly beta1-selective, ultrashort-acting beta-blocker that
could be ideally suited for the treatment of critically ill
patients due to its limited hypotensive effect [35–38].
The aim of this multicenter, prospective, controlled
study is to demonstrate that the administration of the
ultrashort-acting beta-blocker landiolol in patients with
septic shock and persistent tachycardia (HR ≥ 95 beats
per minutes [bpm]) is effective in reducing and main-
taining HR without increasing vasopressor requirements.
Methods/Design
Study design and objective
This is a phase IV, multicenter, prospective, randomized,
open-label, controlled study on landiolol in a septic
shock population (as defined by The Third International
Consensus Definitions for Sepsis and Septic Shock
criteria [39]) hospitalized in an intensive care unit
(ICU). The study duration is expected to be 24 months
from first patient enrolled until completion of the
final visit for the last patient. Participating centers are
listed in Table 1.
The study objective is to compare the percentage of
patients with a HR response (defined as HR within the
target range of 80–94 bpm) and maintenance thereof
without an increase in vasopressor requirements within
the first 24 h of treatment, and to further assess efficacy
and safety in the two treatment arms: standard of care
treatment and landiolol (landiolol group) or standard of
care treatment alone (control group).
Additional file 1 contains the completed Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) checklist.
Study population
This study will enroll a total of 200 patients with septic
shock and elevated HR (≥ 95 bpm) despite a
hemodynamic optimization phase of at least 24 h but a
maximum of 36 h in which they received adequate fluid
resuscitation and continuous vasopressor treatment (ac-
cording to the Surviving Sepsis Campaign Guidelines
2016 [40]). Detailed inclusion and exclusion criteria are
displayed in Table 2.
Randomization, blinding, and treatment allocation
Patients fulfilling the selection criteria are randomized in
a 1:1 ratio to one of the two groups (landiolol or control)
after informed consent, as required by local law, has
been obtained. The presence of atrial fibrillation in the
hemodynamic optimization period is used as a stratifica-
tion factor for randomization. As this is an open label
study, investigators and other study personnel will not
be blinded to the treatment.
Study drug
Lyophilized landiolol hydrochloride 300 mg (Rapibloc
Lyo, 300 mg) is to be reconstituted in 50 mL of 0.9%
NaCl to a concentration of 6 mg/mL before use.
Treatments
Landiolol group
Patients in the landiolol group begin continuous infusion
with landiolol within 2 h after randomization at a start-
ing dose of 1 mcg/kg/min. The dose is to be progres-
sively increased at increments of 1 mcg/kg/min to a
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maximum of 40 mcg/kg/min at intervals of at least
20 min to obtain and maintain a HR of 80–94 bpm.
Landiolol must be infused continuously to maintain the
target HR until one the following events occurs: discon-
tinuation of vasopressor infusion; death; a serious ad-
verse event (AE) attributable to the study drug that
necessitates study drug discontinuation as determined
by the investigator; patient discharge from the ICU; or
day 28 of study participation.
Control group
Patients in the control group receive standard of care
treatment according to the Surviving Sepsis Campaign
Guidelines 2016 [40], which does not specify a target for
HR control. Patients in the control group are to be with-
drawn from the study if they receive beta-blocker
treatment.
Patient assessments
Heart rate, blood pressure, and body temperature will
be documented hourly for the first 24 h after treat-
ment start and every 12 h thereafter in both treat-
ment groups, and additionally at every dose change of
landiolol in the landiolol group. Clinical laboratory
analysis including blood gas analysis will be per-
formed daily for the first four days of the study. Se-
quential Organ Failure Assessment (SOFA) score will
be assessed daily for the first four days and every
third day thereafter. If performed, hemodynamic pa-
rameters (CO, CI, GEDI, ELWI, PAOP, MPAP, LVEF,
TAPSE, VTI) obtained by PICCO/FloTrac, Swan-Ganz
catheter or Cardiac Echo will be documented. Con-
comitant medication and AE will be documented over
the entire study period. Measurements and assess-
ments performed in both groups are listed in Fig. 1
in the completed SPIRIT figure.
Table 1 List of participating centers and ethics committee approvals
Participating center PI Central Ethics committee Reference number Approval date
Medical University Vienna, Department
of Internal Medicine II. Division of
Cardiology
Gottfried Heinz, MD Ethics Committee, Medical
University Vienna
ECS 1805/2017 15 September 2017
Medical University Innsbruck, Division of
Emergency Medicine and Intensive
Care, Department Internal Medicine
Michael Joannidis, MD
State Hospital Wiener Neustadt,
Department of Anesthesiology,
Emergency Medicine and General
Intensive Care
Helmut Trimmel, MD, MSc
University Hospital Greifswald,
Department of Anesthesiology,
Intensive Care, Emergency and Pain
Medicine
Sebastian Rehberg, MD Ethics Committee,
University Hospital
Greifswald
FFV 06/17 15 February 2018
University Hospital Munich, Department
of Anesthesiology
Christian Siebers, MD
University Hospital Hradec Králové,
Department of Anesthesiology,
Resuscitation and Intensive Medicine
Pavel Dostál, MD, PhD, MBA Ethics Committee,
University Hospital Hradec
Králové
201801 I126M 07 November 2017
Masaryk Hospital, Department of
Anesthesiology, Perioperative Medicine
and Intensive Care
Vladimír Černý, MD, PhD, FCCM
University Hospital La Sapienza,
Department of Anesthesiology and
Intensive Care
Andrea Morelli, MD. Ethics Committee,
University Hospital La
Sapienza
4846 08 February 2018
Azienda Ospedaliero Universitaria




Pisana, Department of Anesthesiology
and Resuscitation 6
Francesca Pratesi, MD
University School of Medicine Pisa,
Department of Anesthesiology and
Transplant Intensive Care Unit
Gianni Biancofiore, MD
University Hospital Modena,
Department of Anesthesia and Intensive
Care
Massimo Girardis, MD Approval pending
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Endpoints
The primary efficacy endpoint is HR response (HR =
80–94 bpm) and maintenance thereof without increase
in vasopressor requirements during the first 24 h after
treatment start.
Secondary efficacy endpoints will consist of ICU
and 28-day mortality, ICU and hospital stay duration,
SOFA score, and inotrope and vasopressor support
requirements. Efficacy and safety endpoints are listed
in Table 3.
Data collection
Data will be collected and entered into the electronic
data capture system by trained study personnel (investi-
gators and study nurses).
Sample size
Sample size estimation is based upon the assumption
that 60% of patients in the landiolol group reach the pri-
mary endpoint versus 40% of patients in the control
group. The sample size of 200 patients will provide 80%
power to demonstrate a statistically significant difference
(upon standard level alpha = 0.05) between the treatment
groups using a Chi-square test. The sample size in the
study by Morelli et al. [10] was adequate considering
that to detect a 20% change in HR with a power of 80%
at a level of significance of alpha = 0.05, 64 patients per
group would have been required. In order to detect the
binary primary endpoint of our study an additional 36
patients per group are required.
Statistical analysis
The hypothesis that Group L is superior to Group C in
proportion of patients who reached the primary end-
point will be demonstrated if the lower limit of the
two-sided 95% Newcombe confidence interval of differ-
ence pL-pC is above zero, where pL and pC are percent-
ages of patients who reached the primary endpoint in
Group L and Group C, respectively. P values based on
Cochran–Mantel–Haenszel (according to SAS® termin-
ology) will be presented together with the confidence
intervals to evaluate statistical significance of association
between treatment group and outcome after adjustment
for the stratification group. For the purpose of explora-
tory analysis, the individual criteria of the primary
endpoint, heart rate response (i.e. HR = 80–94 bpm)
reached (also defined as secondary endpoint), heart
rate response reached and maintained and no increase
in vasopressor requirements during the first 24 h, will
be compared separately between treatment groups.
Additional subgroup and sensitivity analyses will have
exploratory character and will be defined in all details
in the SAP.
Secondary endpoints with continuous, ordinal, and
binary variables measured at multiple time-points will be
analyzed as longitudinal data by linear, ordinal logistic,
logistic, or log-binomial regression models with repeated
measures. Covariates used in the models will be (but not
limited to) treatment, visit, stratification group, and
interaction treatment/visit. For continuous variables
baseline value of the outcome variable will be a covariate
as well. Distribution of data and a feasibility check of
planned analyses will be performed before finalization of
SAP and alternative statistical methods will be defined if
assumptions on the application of the planned methods
are not met (e.g. ln-transformation of data, non-para-
metric method, or other alternative way). ICU mortality
and 28-day mortality will be analyzed using the same
methods as for the primary endpoint. Duration of ICU
stay and duration of hospital stay (in survivors/
Table 2 Inclusion/exclusion criteria
Inclusion criteria
1. Informed consent
2. Age ≥ 18 years
3. Confirmed septic shock:
a. Confirmed or suspected infection
b. Acute increase of ≥ 2 points on SOFA Score
c. Need for continuous vasopressor therapy to maintain a mean
arterial pressure (MAP) of > 65 mmHg despite adequate fluid
resuscitation
d. Blood lactate > 2 mmol/L (18 mg/dL)a
4. Tachycardia and/or tachyarrhythmia with heart rate ≥ 95 bpm
5. Norepinephrine infusion rate ≥ 0.2 μg/kg/min at the time of study
inclusion
6. Patients must have undergone a hemodynamic optimization
period of at least 24 h but a maximum of 36 h, during which
period they received continuous vasopressor treatment and
standard treatment for septic shock according to the SSCG 2016
guidelines
aPresence of blood lactate > 2 mmol/L (18 mg/dL) and increase of ≥ 2
points on SOFA score are mandatory for the diagnosis of septic shock,
but must not necessarily be present at the time of study inclusion
Exclusion criteria:
1. Any form of compensatory tachycardia
2. β-blocker treatment within 72 h before randomization
3. Sick sinus syndrome, or second or third degree AV block
4. Patients with any form of cardiac pacing
5. A known serious cardiovascular condition such as ischemic stroke
or transient ischemic attack within the last six months, or pre-
existing heart failure NYHA class III or IV
6. Cardiogenic shock
7. MAP < 65 mmHg
8. Known pulmonary hypertension
9. Known terminal illness other than septic shock with expected
patient’s survival < 28 days
10. Known presence of an advanced condition to withhold life-
sustaining treatment
11. Patients for whom a “Do Not Resuscitate” (DNR) order exists
12. Known sensitivity to any component of the study medication (e.g.
landiolol, mannitol)
13. Participation in a clinical drug trial within 30 days before
randomization
14. Any condition that, in the investigator’s opinion, makes the
individual unsuitable for study participation (to be documented)
15. Pregnant or breast-feeding patients
16. Untreated pheochromocytoma
NYHA New York Heart Association
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non-survivors) will be analyzed as time-to-event data
(using Kaplan–Meier curve and using log-rank test or
Wilcoxon test and/or proportional hazards regression
model if appropriate).
For secondary analyses, no multiplicity adjustment is
planned; therefore, a higher rate of type-I error must be
considered in interpretation of results of secondary ana-
lyses. The analysis of secondary endpoints/analyses can
provide supportive evidence related to the primary ob-
jective, but no confirmatory conclusion based on sec-
ondary analyses can be done.
Discussion
Despite intensive research, morbidity and mortality of
patients with sepsis remain high [39]. Hence, novel
therapeutic concepts are urgently needed. Recently, the
use of beta-blockers during sepsis has been suggested
[10, 28–30, 32, 41]. This represents a true innovation, as
current guidelines recommend beta-mimetics [40]. The
potential benefits of beta-blockers are most likely due to
their pleotropic effects and include myocardial protec-
tion, modulation of inflammatory processes, and im-
provements in organ functions [3, 22, 42–44]. However,
it is still unclear which patients would benefit most from
this intervention.
Morelli et al. [10] (and later others [28–30, 32])
showed that a HR reduction in patients with septic
shock, after adequate resuscitation with fluids, vasopres-
sors, and inotropes, was not associated with an increase
in AEs and did not trigger an increase in vasopressor
support. As in the original protocol by Morelli et al.
[10], the target HR in the present study is < 95 bpm,
which is based on studies showing poorer patient out-
comes when this threshold is exceeded and studies
showing good tolerance after achieving this target with
beta-blockers [7, 11, 45–48]. More recently, several stud-
ies conducted in China [28–30, 32] that selected a simi-
lar HR target showed good tolerance of the beta-blocker
Fig. 1 Schedule of enrolment and assessments (SPIRIT 2013 Figure)
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treatment. Therefore, the HR target of < 95 bpm seems
appropriate for further comparison and optimal with
respect to feasibility and tolerance.
In order to minimize the risk of hemodynamic com-
promise, patients are only included in the study after at
least 24 h of adequate fluid resuscitation and vasopressor
support. In addition, landiolol is started at a low dose of 1
mcg/kg/min (as supported by landiolol sepsis [49], post-
operative [50], and heart failure studies [51]) and titration
is performed conservatively at 20-min intervals (5
half-lives) [35]. The HR target should be reached within
the first 24 h, as supported by published data [28–30, 32].
Esmolol is the beta-blocker that has been most
frequently evaluated in patients with sepsis, as its
pharmacokinetic profile allows for rapid titration when
used intravenously [10, 27–29, 31]. However, landiolol has
demonstrated a more favorable pharmacokinetic and
pharmacodynamic profile than esmolol [52–55]. Landiolol
has a faster onset (1 min vs 2 min) and shorter half-life
(4 min vs 9 min) than esmolol, which should allow for
more rapid titration and enhanced safety [35]. Further-
more, the beta1 selectivity of landiolol is eight times
higher than that of esmolol, resulting in a beta1/beta2 ra-
tio of 255 [35]. This provides landiolol with more pro-
found negative chronotropic effects and a lesser degree of
negative inotropic and hypotensive action [36–38, 56].
This study will investigate whether HR control using
the short-acting beta-blocker landiolol is feasible, safe,
and effective in patients with septic shock and persist-
ent tachycardia, and provide a better understanding of
the potential role of beta-blockers in this patient
population.
Trial status
Protocol version 3.0 dated 3 January 2018. The first par-
ticipant was enrolled on 24 February 2018.
Additional file
Additional file 1: Checklist_SPIRIT_guidelines.pdf, Checklist of the
Standard Protocol Items: Recommendations for Interventional Trials
(SPIRIT) guidelines. (PDF 129 kb)
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